Karyopharm Therapeutics Inc. has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025. These RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with one-third vesting on each anniversary of the grant date, contingent upon the employees' continued service. Additionally, the RSUs will become fully exercisable if the employee's employment is terminated for "good reason" or without "cause" within a year of a "change in control event."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。